 htm 23553 Material contracts 10 2017-03-22T05:31:45.236347-05:00 Filing 0001493152-17-002701 2017-03-22 10-K Annual  & Quarterly Reports 0001505497 BioRestorative Therapies, Inc. BRTX BRTXW COMMON OTC 8090 Miscellaneous Health  & Allied Services, Not Elsewhere Classified No NEW YORK DELAWARE DELAWARE Stem Cell Assurance, Inc. false Small Reporting Company 001-37603 EX-10.37 Exhibit Exhibit 4 ex10-37.htm EX-10.37 4 ex10-37.htm 
 
   
 Exhibit 10.37 
   
 BioRestorative Therapies, Inc. 
 40 Marcus Drive, Suite One 
 Melville, New York 11747 
   
   March 1, 2017 
   
 Mr. Edward L. Field 
 3706 St. Marks Road 
 Durham, North Carolina 27707 
   
 Dear Mr. Field: 
   
Reference is made to the Executive Employment Agreement, dated as of February 9, 2015, between BioRestorative Therapies, Inc. (the "Company") and you (the "Executive"), as amended (the "Employment Agreement"). All capitalized terms used and not defined herein shall have the meanings ascribed to them in the Employment Agreement. 
   
Pursuant to the Employment Agreement, the Executive is entitled to receive an annual bonus of up to 30% of his Per Annum Salary based upon the satisfaction of certain performance goals. The parties agree that, for the year ended December 31, 2016, the Executive instead is entitled to receive an annual bonus of up to 24% of his Per Annum Salary based upon the satisfaction of the revised performance goals set forth on Schedule A attached hereto. The Company acknowledges and agrees that, as of the date hereof, the initial two (2) perform ance goals set forth on Schedule A have been satisfied. 
   
The parties agree further that the performance goals for the year ending December 31, 2017, and the bonus amount payable with respect thereto, are as set forth on Schedule B attach ed hereto. 
   
Except as amended hereby, the Employment Agreement shall continue in full force and effect in accordance with its terms. 
   
   Very truly yours,         BioRestorative Therapies, Inc.         By:       Mark Weinreb, Chief Executive Officer 
   
 Agreed:       
 
 Edward L. Field 
   
   
 
 
 
   
 
 
   
 
 
   
 SCHEDULE A 
   
 2016 Bonus Milestones: 
   
 ●$36,000 in the event the Company files an IND application with regard to the commencement of a clinical trial for the Company's BRTX-100 product (the "Clinical Trial") (the "IND Ap plication") with the Food and Drug Administration (the "FDA");     ● $18,000 in the event the FDA clears the IND Application;     ●$18,000 upon testing and receipt of certification that the Company's fully equipped cleanroom has attained an ISO Class 7 cleanliness level. 
   
It is understood and agreed that (i) the filing of the IND Application with the FDA had to be achieved by December 31, 2016 in order for the Executive to be entitled to receive the Bonus amount; and (ii) the other milestones may occur by July 31, 2017. In addition, the Executive must have remained continuously employed with the Company through the date on which a particular milestone is satisfied in order for the Executive to be entitled to receive the particular Bonus amount. Any issue as to whether any of the foregoing milestones ha ve been satisfied shall be determined by the Company in its sole discretion. 
   
 
 
 
   
 
 
   
 
 
   
 SCHEDULE B 
   
 2017 Bonus Milestones: 
   
 ● $18,000 in the event of IRB approval at one site to commence the Clinical Trial;     ● $36,000 in the event a patient in the Clinical Trial receives a dose of BRTX-100;     ● $18,000 in the event at least six patients enroll in the Clinical Trial;     ●$18,000 in the event the Company completes two mock production runs of BRTX-100 in its cleanroom in which BRTX-100 meets all specified product release requirements 
   
It is understood and agreed that each of the foregoing milestones must be achieved by December 31, 2017 in order for the Executive to be entitled to receive the Bonus amount. In addition, the Executive must have remained continuously employed with the Company through the date on which a particular milestone is satisfied in order for the Executive to be entitled to receive the particular Bonus amount. Any issue as to whether any of the foregoing milestones have been satisfied shall be determined by the Company in its sole discretion. 
   
 
 
   
 
 
   
 
 
   
